Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON37724
NL-OMON37724CompletedNot Applicable

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study and an Open-Label Relative Bioavailability and Food Effect Study of VX-787 in Healthy Subjects - VX-787 SAD/MAD study

Vertex Pharmaceuticals0 sites56 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
56
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •healthy male and female subjects
  • •18-55 yrs, inclusive
  • •BMI: 18.0-31.0 kg/m2, inclusive
  • •non-smoking

Exclusion Criteria

  • •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Investigators

Similar Trials

Completed
Unknown
A Phase 1 study, oral VVZ2471 in healthy male volunteers
KCT0008891Vivozon87
Recruiting
Phase 1
Investigation of AV411 in Healthy SubjectsHealthy subjectsOther -
ACTRN12606000410550Avigen, Inc.16
Not yet recruiting
Phase 1
A Phase 1, Randomized Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intermittent Consecutive Day Dosing Regimen of PRTX007 in Healthy Adultsassa VirusLassa VirusInfection - Other infectious diseases
ACTRN12624000981527nited States Defense Threat Reduction Agency (DTRA)15
Completed
Phase 1
A Phase I, Randomised, Double-Blinded, Placebo Controlled, Safety and Pharmacokinetic Study of (Z)-Endoxifen in Healthy Female VolunteersEstrogen Receptor Positive (ER+) breast cancerCancer - Breast
ACTRN12619000961145Atossa Genetics AUS Pty Ltd25
Completed
Phase 1
A Phase I, Randomised, Double-Blinded, Placebo Controlled, Safety and Pharmacokinetic Study of (Z)-Endoxifen Tablets in Healthy Female VolunteersEstrogen Receptor Positive (ER+) Breast CancerCancer - Breast
ACTRN12619001623189Atossa Genetics Aus Pty Ltd12